Login
Companies $GH
$147.54 +$3.51 (2.44%) After hours
Guardant Health, Inc. logo

Guardant Health, Inc.

guardanthealth.com

What Do They Do?

Sells blood and tissue tests for cancer treatment selection, disease monitoring and colorectal cancer screening to physicians, hospitals and cancer centers. Also provides tests and data services to biopharmaceutical companies.

How Do They Make Money?

For oncology tests, the company earns revenue when results are reported to physicians, with patients, commercial and government payers, hospitals and cancer centers among those paying. Biopharma customers pay per test or for testing and related services over time or at milestones; the company also earns revenue by licensing technology.

revenue
SegmentShareRevenue
Oncology
Sold outright

70%
Biopharma and data
Mix

21%
Screening
Sold outright
8.1%
Licensing and other
Licensed
0.9%

Who Are Their Customers?

Hospitals, cancer centers, research institutions and patients are clinical customers; tests are also delivered through laboratories operated by strategic partners. Biopharma companies buy tests and development, data and referral services, while international laboratory partners and distributors are also customers.

Do Revenues Turn Into Profits?

No. It lost $416.3M in FY2025.

Operating income, FY2025
−45% of revenue
▲ +1% (Loss) vs FY2024 (−$443.6M, −60%)
Net income, FY2025
−42% of revenue
▲ +5% (Loss) vs FY2024 (−$436.4M, −59%)
Free cash flow, FY2025
−24% of revenue
▲ +15% (Loss) vs FY2024 (−$274.9M, −37%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +36%
vs $265.2M in Q3 FY2025
Net income
▼ −34% (Loss)
vs −$92.7M in Q3 FY2025
Oncology share of revenue vs 69.5% in Q3 FY2025

Growing. Revenue grew 2.6x in 4 years, from $373.7M in FY2021 to $982M in FY2025, about 27% a year.

Shield screening status The older report described Shield as a laboratory-developed test and planned an FDA submission; the latest describes it as FDA-approved for primary colorectal cancer screening and meeting Medicare coverage requirements.

Revenue over time
Oncology Biopharma and data Screening Licensing and other
$1B$500M$0

Who Do They Compete With?

Competes with Foundation Medicine, Caris Life Sciences, Tempus AI, NeoGenomics, Exact Sciences, BillionToOne, Quest Diagnostics, Laboratory Corporation of America, Natera, Myriad Genetics, Personalis, GRAIL, Freenome Holdings, Delfi Diagnostics, Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, Ultima Genomics, and Oxford Nanopore Technologies

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support